Recent updates and perspectives on leishmaniasis

Journal of Infection in Developing Countries

Volumn 9, Issue 6, 2015, Pages 588-596

  Savoia, Dianella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Diagnosis; Immunotherapy; Leishmaniasis; Treatment

Indexed keywords

ALOE VERA EXTRACT; AMPHOTERICIN B; ARTEMISIA ANNUA EXTRACT; CA272; CANINE VACCINE; CH872; CHENOPODIUM AMBROSIOIDES EXTRACT; CROVIRIN; DNDI VI 2098; ENZYME; FEXINIDAZOLE; HYPTIS PECTINATA EXTRACT; KINETOPLASTID TOPOISOMERASE; MILTEFOSINE; NIFURTIMOX; NITROIMIDAZOLE; PAROMOMYCIN; PEFLOXACIN; PFAFFIA GLOMERATA EXTRACT; PLANT EXTRACT; PRETOMANID; RESVERATROL; RUTA GRAVEOLENS EXTRACT; SCYX 7158; SECRETORY PROTEIN; TRYPANOTHIONE REDUCTASE; TRYPANOTHIONE SYNTHETASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; ZINC OXIDE NANOPARTICLE; ANTIPROTOZOAL AGENT;

ARTICLE; ASPARAGUS RACEMOSUS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNITY; IMMUNOFLUORESCENCE TEST; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS; MICROSCOPY; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PHOTODYNAMIC THERAPY; POLYMERASE CHAIN REACTION; SERODIAGNOSIS; VACCINATION; WESTERN BLOTTING; WITHANIA SOMNIFERA; AFRICA; ANIMAL; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DISEASE CARRIER; IMMUNOLOGY; PARASITOLOGY; PROCEDURES; PSYCHODIDAE; SOUTH AND CENTRAL AMERICA; SOUTHEAST ASIA; SOUTHERN EUROPE;

PHLEBOTOMINAE;

AFRICA, EASTERN; ANIMALS; ANTIPROTOZOAL AGENTS; ASIA, SOUTHEASTERN; DEVELOPING COUNTRIES; DIAGNOSTIC TESTS, ROUTINE; HUMANS; INSECT VECTORS; LATIN AMERICA; LEISHMANIA; LEISHMANIASIS; MEDITERRANEAN REGION; PSYCHODIDAE;

EID: 84936882055     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.6833     Document Type: Article

References (76)

1. World Health Organization (2014) Global Health Observatory Data – Leishmaniasis. Available at: http://www.who.int/gho/neglected_diseases/leishmaniasis/en/ Global Health Observatory. Accessed on April 21, 2015.
2. Pace D (2014) Leishmaniasis. J Infect 69 S10-18.
3. Khyatti M, Trimbitas RD, Zouheir Y, Benani A, El Messaoudi MD, Hemminki K (2014) Infectious diseases in North Africa and North African immigrants to Europe. Eur J Public Health 24 Suppl 1: 47-56.
4. Field V, Gautret P, Schlagenhauf P, Burchard GD, Caumes E, Jensenius M, Castelli F, Gkrania-Klotsas E, Weld L, Lopez-Velez R, de Vries P, von Sonnenburg F, Loutan L, Parola P; EuroTravNet network (2010) Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis 10: 330.
5. Okwor I, Uzonna JE (2013) The immunology of leishmania/HIV coinfection. Immunol Res 56: 163-171.
6. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; WHO Leishmaniasis Control Team (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7: e35671.
7. De Vries HJ, Reedijk SH, Schallig HD (2015) Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol 16: 99-109.
8. Arce A, Estirado A, Ordobas M, Sevilla S, García N, Moratilla L, de la Fuente S, Martínez AM, Pérez AM, Aránguez E, Iriso A, Sevillano O, Bernal J, Vilas F (2013) Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012. Euro Surveill 18: 20546.
9. Varani S, Cagarelli R, Melchionda F, Attard L Salvadori C, Finarelli AC, Gentilomi GA, Tigani R, Rangoni R, Todeschini R, Scalone A, Di Muccio T, Gramiccia M, Gradoni L, Viale P, Landini MP (2013) Ongoing outbreak of visceral leishmaniasis in Bologna Province, Italy, November 2012 to May 2013. Euro Surveill 18: 20530.
10. de Silva TI, Debroy Kidambi A, Green ST, Mahadeva U, Mcgregor AC, Levy M, Hardcastle N (2015) Cutaneous leishmaniasis acquired during a brief visit to Cyprus. J Infect 70: 314-316.
11. Monge-Maillo B, Norman F, Cruz I, Alvar J, Lopez-Velez R (2014) Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLoS Negl Trop Dis 8, e3021
12. Singh S (2014) Changing trends in the epidemiology, clinical presentation, and diagnosis of Leishmania-HIV co-infection in India. Int J Infect Dis 29:103-112.
13. Clemente W, Vidal E, Girão E, Ramos AS, Govedic F, Merino E, Muñoz P, Sabé N, Cervera C, Cota GF, Cordero E, Mena A, Montejo M, López-Medrano F, Aguado JM, Fernandes P, Valerio M, Carratalá J, Moreno A, Oliveira J, Mourão PH, Torre-Cisneros J (2015) Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect 21: 89-95.
14. World Health Organization, Regional Office for Europe (2014) Strategic framework for-leishmaniasis control in the WHO European Region 2014-2010. Available at: www.euro.who.int/_data/assets/pdf_file/0017/245330/ Accessed on day/month/year.
15. Diniz SA, Silva FL, Carvalho Neta AV, Bueno R, Guerra RM, Abreu-Silva AL, Santos RL (2008) Animal reservoirs for visceral leishmaniasis in densely populated urban areas. J Infect Dev Ctries 2: 24-33. doi:10.3855/jidc.318.
16. Turchetti AP, Souza TD, Paixao TA, Santos RL. (2014) Sexual and vertical transmission of visceral leishmaniasis. J Infect Dev Ctries 8: 403-407. doi:10.3855/jidc.4108.
17. Cecilio P, Perez-Cabezas B, Santarem N, Maciel J, Rodrigues V, Cordeiro da Silva A (2014) Deception and manipulation: the arms of Leishmania, a successful parasite. Front Immunol 5: 480.
18. Gandacu D, Glazer Y, Anis E, Karakis I Warshavsky B, Slater P, Grotto I (2014) Resurgence of cutaneous leishmaniasis in Israel, 2001–2012. Emerg Infect Dis 20: 1605-1611.
19. Bettaieb J, Toumi A, Chlif S, Chelghaf B, Boukthir A, Gharbi A, Ben Salah A (2014) Prevalence and determinants of Leishmania major infection in emerging and old foci in Tunisia. Parasit Vectors 7: 386.
20. Saroufim M, Charafeddine K, Issa G, Khalifeh H, Habib RH, Berry A, Ghosn N, Rady A, Khalifeh I (2014) Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon. Emerg Infect Dis 20: 1712-1715.
21. Crowe A, Slavin J, Stark D, Aboltins C (2014) A case of imported Leishmania infantum cutaneous leishmaniasis; an unusual presentation occurring 19 years after travel. BMC Infect Dis 14: 597.
22. Maroli M, Feliciangeli MD, Bichaud L, Charrel RN, Gradoni L (2013) Phlebotomine sandflies and the spreading of leishmaniases and other diseases of public health concern. Med Vet Entomol 27: 123-147.
23. Signorini M, Cassini R, Drigo M, Frangipane di Regalbono A, Pietrobelli M, Montarsi F, Stensgaard AS (2014) Ecological niche model of Phlobotomus perniciosus, the main vector of canine leishmaniasis in north-eastern Italy. Geospat Health 9: 193-201.
24. Mansueto P, Seidita A, Vitale G, Cascio A (2014) Leishmaniasis in travelers: a literature review. Travel Med Infect Dis 12: 563-581.
25. Elmahallawy EK, Sampedro Martínez A, Rodriguez-Granger J, Hoyos-Mallecot Y, Agil A, Navarro Mari JM, Gutierrez Fernandez J (2014) Diagnosis of leishmaniasis. J Infect Dev Ctries 8: 961-972. doi:10.3855/jidc.4310.
26. Lemrani M, Hamdi S, Laamrani A, Hassar M (2009) PCR detection of Leishmania in skin biopsies. J Infect Dev Ctries 3: 115-122. doi:10.3855/jidc.511.
27. Santos TR, Carreira VS, Ferrari HF, Moreira MA, Luvizotto MC (2014) Comparison of PCR with stained slides of bone marrow and lymph nodes aspirates with suspect diagnosis for leishmaniasis. Acta Tropica 140: 137-140.
28. Mohapatra TM, Singh DP, Sen MR, Bharti K, Sundar S (2010) Comparative evaluation of rK9, rK26 and rK39 antigens in the serodiagnosis of Indian visceral leishmaniasis. J Infect Dev Ctries 4: 114-117. doi:10.3855/jidc.544.
29. Vallur AC, Hailu A, Mondal D, Reinhart C, Wondimu H, Tutterrow Y, Ghalib HW, Reed SG, Duthie MS (2014) Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis. Eur J Clin Microbiol Infect Dis 34: 679-686.
30. Celeste BJ, Arroyo Sanchez MC, Ramos-Sanchez EM, Castro LG, Lima Costa FA, Goto H (2014) Recombinant Leishmania infantum heat shock protein 83 for the serodiagnosis of cutaneous, mucosal, and visceral leishmaniasis. Am J Trop Med Hyg 90: 860-865.
31. Zucca M, Scutera S, Savoia D (2013) New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases. Curr Med Chem 20: 502-526.
32. Sinha PK, Bhattacharya S (2014) Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis. Lancet Glob Health 2: e7-8.
33. Hodiamont CJ, Kager PA, Bart A, de Vries HJ, van Thiel PP, Leenstra T, de Vries PJ, van Vugt M, Grobusch MP, van Gool T (2014) Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis 8: e2832.
34. Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P (2014) Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. PLoS Negl Trop Dis 8: e3169.
35. Ferreira C, Soares DC, Nascimento MT, Pinto-da-Silva LH, Sarzedas CG, Tinoco LW, Saraiva EM (2014) Resveratrol is active against Leishmania amazonensis: in vitro effect of its association with amphotericin B. Antimicrob Agents Chemother 58: 6197-6208.
36. Sinha PK, Jha T.K, Thakur CP, Nath D, Mukherjee S, Aditya AK, Sundar S (2011) Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med 2011, 645203.
37. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543-550.
38. Das S, Rani, M, Pandey K, Sahoo GC, Rabidas VN, Singh D, Das P (2012) Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro. J Antimicrob Chemother 67: 2373-2378.
39. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, Read KD, Fairlamb AH (2012) The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 4: 119re1
40. Colotti G, Ilari A (2011) Polyamine metabolism in Leishmania: from arginine to trypanothione. Amino Acids 40: 269-285.
41. Pereira BA, Souza-Silva F, Silva-Almeida M, Santos-de-Souza R, Gonçalves de Oliveira LF, Ribeiro-Guimarães ML, Alves CR (2014) Proteinase inhibitors: a promising drug class for treating leishmaniasis. Current Drug Targets 15: 1121-1131.
42. Savoia D, Allice T, Tovo PA (2005) Antileishmanial activity of HIV protease inhibitors. Int J Antimicrob Agents 26: 92-94.
43. White RE, Powell DJ, Berry C (2011) HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites. FASEB J 25: 1729-1736.
44. Chowdhury S, Majumder HK (2015) Inhibitors of DNA topoisomerases as potential antileishmanial agents. In: Leishmania: Current Biology and Control. Publ Caister Academic Press, Ed: Adak S and Datta R, CSIR India.
45. Zucca M, Millesimo M, Giovarelli M, Diverio D, Musso T, Savoia D (1996) Protective role of the pefloxacin-IFN-gamma association in Leishmania major-infected mice. New Microbiol 19: 39-46.
46. Rajasekaran R, Chen YP (2012) Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads. J Mol Model 18: 4089-4100.
47. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, Nam J, Jang J, Cechetto J, Lee CB, Moon S, Genovesio A, Chatelain E, Christophe T, Freitas-Junior LH (2010) Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis 4: e675.
48. Prati F, Goldman-Pinkovich A, Lizzi F, Belluti F, Koren R, Zilberstein D, Bolognesi ML (2014) Quinone-amino acid conjugates targeting Leishmania amino acid transporters. PLoS One 9: e107994.
49. Nagle AS, Khare S, Kumar AB, Supek F, Buchynskyy A, Mathison CJ, Chennamaneni NK, Pendem N, Buckner FS, Gelb MH, Molteni V (2014) Recent developments in drug discovery for leishmaniasis and human african trypanosomiasis. Chem Rev PMID 25365529.
50. Gupta S, Yardley V, Vishwakarma P, Shivahare R, Sharma B, Launay D, Martin D, Puri SK (2015) Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. J Antimicrob Chemother 70: 518-527.
51. Tiwari A, Kumar S, Shivahare R, Kant P, Gupta S, Suryawanshi SN (2015) Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents. Bioorg Med Chem Lett 25: 410-413.
52. Abengózar MÁ, Bustos LA, García-Hernández R, Fernández de Palencia P, Escarcena R, Castanys S, del Olmo E, Gamarro F, San Feliciano A, Rivas L (2015) Mechanisms of action of substituted β-amino alkanols on Leishmania donovani. Antimicrob Agents Chemother 59: 1211-1218.
53. Azevedo EG, Ribeiro RR, da Silva SM, Ferreira CS, de Souza LE, Ferreira AA, de Oliveira E Castro RA, Demicheli C, Rezende SA, Frézard F (2014) Mxed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis. Expert Opin Drug Deliv 11: 1551-1560.
54. Adade CM, Carvalho AL, Tomaz MA, Costa TF, Godinho JL, Melo PA, Lima AP, Rodrigues JC, Zingali RB, Souto-Padrón T (2014) Crovirin, a snake venom cysteine-rich secretory protein (CRISP) with promising activity against Trypanosomes and Leishmania. PLoS Negl Trop Dis 8: e3252.
55. De Queiroz AC, Dias Tde L, Da Matta CB, Cavalcante Silva LH, de Araújo-Júnior JX, de Araújo GB, Moura Fde B, Alexandre-Moreira MS (2014) Antileishmanial activity of medicinal plants used in endemic areas in northeastern Brazil. Evid Based Complement Alternat Med 2014: 478290
56. de Morais SM, Vila-Nova NS, Bevilaqua CM, Rondon FC, Lobo CH, de Alencar Araripe Noronha Moura A, Sales AD, Rodrigues AP, de Figuereido JR, Campello CC, Wilson ME, de Andrade HF. (2014) Thymol and eugenol derivatives as potential antileishmanial agents. Bioorg Med Chem 22: 6250-6255.
57. Islamuddin M, Chouhan G, Tyagi M, Abdin MZ, Sahal D, Afrin F (2014) Leishmanicidal activities of Artemisia annua leaf essential oil against visceral leishmaniasis. Front Microbiol 5: 626.
58. Nadhman A, Nazir S, Khan MI, Arooj S, Bakhtiar M, Shahnaz G, Yasinzai M (2014) PEGylated silver doped zinc oxide nanoparticles as novel photosensitizers for photodynamic therapy against Leishmania. Free Radic Biol Med 77: 230-238.
59. Enk CD, Nasereddin A, Alper R, Dan-Goor M, Waffe CL, Wulf HC (2014) Cutaneous leishmaniasis responds to daylight-activated photodynamic therapy: proof-of-concept for a novel self-administered therapeutic modality. Br J Dermatol PMID 25363817.
60. Peña S, Scarone L, Serra G (2015) Macrocycles as potential therapeutic agents in neglected diseases. Future Med Chem 4: 1-28.
61. Foroughi-Parvar F, Hatam G (2014) Vaccines for canine leishmaniasis. Adv Prev Med 2014: 569193.
62. Gradoni L (2015) Canine Leishmania vaccines: still a long way to go. Vet Parasitol 208: 94-100.
63. Sacks DL (2014) Vaccines against tropical parasitic diseases: a persisting answer to a persisting problem. Nat Immunol 15: 403-405.
64. Khadem F, Uzonna JE (2014) Immunity to visceral leishmaniasis: implications for immunotherapy. Future Microbiol 9: 901-915.
65. Joshi S, Rawat K, Yadav NK, Kumar V, Siddiqi MI, Dube A (2014) Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches. Front Immunol 5: 380.
66. Singh OP, Sundar S (2014) Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol 5: 296.
67. Kumar R, Singh N, Gautam S, Singh OP, Gidwani K, Rai M, Sacks D, Sundar S, Nylén S (2014) Leishmania specific CD4 T cells release IFNγ that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl Trop Dis 8: e3198.
68. Chowdhury BP, Bandyopadhyay S, Das S, Majumder S, Jha MK, Majumdar SB, Saha B, Majumdar S (2015) The Host-protective effect of arabinosylated lipoarabinomannan against Leishmania donovani infection is associated with restoration of IFN-γ responsiveness. PLoS One 10: e01 17247.
69. Nascimento MS, Carregaro V, Lima-Júnior DS, Costa DL, Ryffel B, Duthie MS, de Jesus A, de Almeida RP, da Silva JS (2014) Interleukin 17A acts synergistically with interferon γ to promote protection against Leishmania infantum infection. J Infect Dis 211: 1015-1026.
70. Dasgupta S, Aghazadeh-Dibavar S, Bandyopadyay M (2014) The role of toll-like receptor agonists in the immunotherapy of leishmaniosis. An update and proposal for a new form of anti-leishmanial therapy. Ann Parasitol 60: 75-82.
71. Lima Maciel BL, Valverde JG, Rodrigues-Neto JF, Freire-Neto F, Keesen TS, Jeronimo SM (2014) Dual immune modulatory effect of vitamin A in human visceral leishmaniasis. PLoS One 9: e107564.
72. Kaur S, Chauhan K, Sachdeva H (2014) Protection against experimental visceral leishmaniasis by immuno stimulation with herbal drugs derived from Withania somnifera and Asparagus racemosus. J Med Microbiol 63: 1328-1338.
73. Costa LE, Goulart LR, Pereira NC, Lima MI, Duarte MC, Martins VT, Lage PS, Menezes-Souza D, Ribeiro TG, Melo MN, Fernandes AP, Soto M, Tavares CA, Chávez-Fumagalli MA, Coelho EA. (2014) Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis. PLoS One 9: e110014.
74. Colhone MC, Silva-Jardim I, Stabeli RG, Ciancaglini P (2014) Nanobiotechnologic approach to a promising vaccine prototype for immunisation against leishmaniasis: a fast and effective method to incorporate GPI-anchored proteins of Leishmania amazonensis into liposomes. J Microencapsul 29: 1-8.
75. Caldeira LR, Fernandes FR, Costa DF, Frezard F, Afonso LC, Ferreira LA (2015) Nanoemulsions loaded with amphotericin B. a new approach for the treatment of leishmaniasis. Eur J Pharm 70C: 125-131.
76. Hayden EC (2014) Projects set to tackle neglected diseases. Nature 505:142.